Deborah Holubec, MD
Pain Management · Allen, TXNPI 1831169077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 76 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Arbor Pharmaceuticals, Inc. at 35.3% of the total. Reporting peaked in 2020 at $287 and has fallen 72.3% since, to $79 in 2024.
Across 76 payments — averaging $15.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arbor Pharmaceuticals, Inc.$409
- Medtronic$159
- Azurity Pharmaceuticals, Inc.$89
- Biohaven Pharmaceutical Holding Company Ltd.$74
- Assertio Therapeutics, Inc.$60
- AbbVie$58
- plus $311 from 13 others
What the payments were for
- Food & beverage$1,161100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arbor Pharmaceuticals, Inc. | 32 | $409 |
| Medtronic(2 entities) | 12 | $159 |
| Azurity Pharmaceuticals, Inc. | 5 | $89 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $74 |
| Assertio Therapeutics, Inc. | 3 | $60 |
| AbbVie | 3 | $58 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Averitas Pharma Inc. | 2 | $48 |
| Boston Scientific | 3 | $46 |
| Redhill Biopharma Inc. | 1 | $23 |
| Trevena, Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Abbott | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Sentynl Therapeutics, Inc. | 1 | $14 |
| Fidia Pharma USA Inc. | 1 | $14 |
| Avanos Medical | 1 | $13 |
| IBSA Pharma Inc. | 1 | $12 |
How this compares
Too few pain management providers in Texasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MovantikNaloxegol Oxalate | 18 | $7,203 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 227 | $6,905 |
| Fentanyl | 22 | $3,249 |
| Morphine Sulfate ErMorphine Sulfate | 78 | $2,834 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 46 | $2,292 |
| Gabapentin | 130 | $1,590 |
| Pregabalin | 25 | $1,470 |
| Oxycodone Hcl | 53 | $1,282 |
| Methocarbamol | 28 | $682 |
| Trazodone Hcl | 25 | $574 |
| Cyclobenzaprine Hcl | 38 | $369 |
| Tizanidine Hcl | 23 | $153 |
| Amitriptyline Hcl | 13 | $106 |
| Temazepam | 16 | $104 |
| Tramadol Hcl | 16 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Redhill Biopharma Inc.Movantik | $23 | $7,20318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pain management providers in Texason file to place this against a meaningful peer group, so we don't.
Other pain management in Allen
- Shahid RashidMcAllen$2K
- Cathryn BrownKaty$386
- Deborah WestergaardDallas$208
- Mary DinhGeorgetown$40
- Vaheh DavoudianPlano$0
- Oluwole OladuteSugar Land$0
- Thomas VetterAustin$0
- Abraham ThomasBellaire$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.